H
Hangzhou Jieyi Biotechnology
A high-technology enterprise focusing on generic testing and using molecular technology as the platform
About Hangzhou Jieyi Biotechnology
MatriDx is a pioneering company in the field of molecular diagnostics, specializing in the detection and treatment of infectious diseases. The company leverages advanced technologies such as CRISPR Cas gene editing and high-throughput sequencing (NGS) to provide comprehensive diagnostic solutions. MatriDx serves healthcare providers, hospitals, and research institutions primarily in the Chinese market. Its business model revolves around offering a range of diagnostic instruments, reagents, and complete mNGS (metagenomic next-generation sequencing) solutions. The company generates revenue through the sale of its diagnostic products and services, as well as through strategic partnerships and collaborations. MatriDx has established a robust portfolio of core technologies and patents, ensuring high-quality and reliable diagnostic outcomes. Recent collaborations, such as the agreement with GoBroad Healthcare Group, aim to enhance precision diagnosis and treatment in oncology. MatriDx's solutions are designed to make diagnosis simpler, faster, and more intelligent, ultimately improving patient outcomes.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2019
- Headquarters
- Hangzhou, China
- Employees
- 7
- Open positions
- None listed
- Dealroom signal
- 25.7/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Precision Medicine, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Feb 2024 | $28M | $413M | Hangzhou Yuhang Financial Holding Group · Quintiles Investments · Yuhang Transformation and Upgrading Industry Fund | ↗ |
| FundingOther financing | Sep 2021 | — | — | Qianhai FOF · Proxima Ventures · Alibaba · Huatai Zijin Investment | ↗ |
Growth signals
Latest recorded traffic for Hangzhou Jieyi Biotechnology is 320 monthly website visits, down 67% over the last three months. Hangzhou Jieyi Biotechnology's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
Proxima Ventures- PCPuhua Capital
Series A1 investor entered at this stage
CD Capital
Series B and later3 investors entered at this stage
- HGHangzhou Yuhang Financial Holding Group
- QIQuintiles Investments
- YFYuhang Transformation and Upgrading Industry Fund
Other known investors3 additional known investors
Alibaba
Huatai Zijin Investment
Qianhai FOF
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Hangzhou Jieyi Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Hangzhou Jieyi Biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.